Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |
2. |
ECCT/23/04/02 | Shigella 53G study in Kenya Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study |
Principal Investigator(s) 1. Melissa Kapulu 2. Fredrick Sawe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
3. |
ECCT/23/11/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD) |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. In this submission: International Cancer Institute (Uasin Gishu county) |
View |
4. |
ECCT/23/09/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD) |
Principal Investigator(s) 1. Doreen Terry Karimi Site(s) in Kenya Gertrudes Childrens Hospital |
View |
5. |
ECCT/24/06/04 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N) (Machakos county) |
View |